MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.parkreldis.2026.108265

Медицинская библиотека · Parkinsonism & related disorders · 2026

Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies.

Hasoon Jahfer, Hamilton Calum A, Firbank Michael, Schumacher Julia, Colloby Sean J, Donaghy Paul C, Taylor John-Paul, Thomas Alan J

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Predicting conversion to dementia in mild cognitive impairment with Lewy bodies (MCI-LB) remains challenging. Furthermore, there is limited research combining predictive markers in MCI-LB. We explored the utility of Lewy body and Alzheimer's disease biomarkers for the prediction of future decline in MCI-LB.

METHODS

Eighty-seven participants were included (35 MCI-AD, 15 possible MCI-LB, 37 probable MCI-LB). Baseline assessment involved MRI, EEG, bloods and cognitive testing. Follow up was completed yearly with review of diagnosis and repeat cognitive testing. We evaluated the relationship between baseline biomarkers and dementia-free survival time. We also investigated biomarker effects on future cognitive decline using annualised change in ACE-R. The value of combining biomarkers with baseline cognitive test score was assessed using forward selection.

RESULTS

In probable MCI-LB, shorter dementia-free survival time was strongly associated with smaller hippocampal volume (hazard ratio = 2.36, 95% CI 1.41 - 3.94) and smaller posterior cortical volume (hazard ratio = 2.62, 95% CI 1.35 - 5.10). Reduced EEG dominant frequency, increased relative delta and theta power, reduced insula volume, increased plasma tau, and increased plasma GFAP were also associated with an increased hazard ratio. Posterior atrophy, hippocampal atrophy, and GFAP were significant predictors of ACE-R decline. Combining blood and MRI biomarkers improved model quality for dementia-free survival (GFAP and hippocampal atrophy) and cognitive test decline (AB ratio and posterior atrophy).

CONCLUSION

Blood, EEG and MRI biomarkers of dementia with Lewy bodies, neurodegeneration and Alzheimer's co-pathology demonstrate utility for prognosis in MCI-LB. Combining biomarkers across modalities improves prognostic accuracy.

Для цитирования: Hasoon Jahfer, Hamilton Calum A, Firbank Michael, Schumacher Julia, Colloby Sean J, Donaghy Paul C, Taylor John-Paul, Thomas Alan J. Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies.. Parkinsonism & related disorders. 2026. DOI: 10.1016/j.parkreldis.2026.108265.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.